cat no | ioEA1006
A rapidly maturing, consistent and scalable isogenic system to study amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
ioGlutamatergic Neurons TDP‑43 M337V/WT are opti‑ox™ precision reprogrammed glutamatergic neurons carrying a genetically engineered heterozygous M337V mutation in the TARDBP gene, encoding TAR DNA binding protein 43 (TDP‑43).
Related disease model cells are available with a homozygous TDP‑43 M337V/M337V mutation, and both can be used alongside their genetically matched control, ioGlutamatergic Neurons™.
Request a quote
Once your quote request has been submitted, one of our sales team will be in contact.
Make True Comparisons
Pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to investigate the impact of mutant TDP‑43 protein on disease progression.
Scalable
Industrial scale quantities are available with industry-leading seeding densities, and at a price point that allows the cells to be used from research to high throughput screening.
Quick
The disease model cells and isogenic control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.
Starting material
Human iPSC line
Karyotype
Normal (46, XY)
Seeding compatibility
6, 12, 24, 48, 96 & 384 well plates
Shipping info
Dry ice
Donor
Caucasian adult male (skin fibroblast)
Vial size
Small: >1 x 10⁶ viable cells
Large: >5 x 10⁶ viable cells
Quality control
Sterility, protein expression (ICC), genotype (Sanger seq) and gene expression (RT-qPCR)
Product use
These cells are for research use only
Differentiation method
opti-ox cellular reprogramming
Recommended seeding density
30,000 cells/cm2
User storage
LN2 or -150°C
Format
Cryopreserved cells
Applications
FTD and ALS research
Drug discovery and development
Disease modelling
High-throughput screening
Electrophysiological assays (MEA)
Co-culture studies
Genetic modification
Heterozygous M337V missense mutation in the TARDBP gene
ioGlutamatergic Neurons TDP‑43 M337V/WT express neuron-specific markers with protein expression highly reminiscent to the isogenic control
Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins MAP2 and TUBB3 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons TDP‑43 M337V/WT compared to the isogenic control. 100X magnification.
ioGlutamatergic Neurons TDP‑43 M337V/WT form structural neuronal networks by day 11
ioGlutamatergic Neurons TDP‑43 M337V/WT mature rapidly and form structural neuronal networks over 11 days when compared to the isogenic control. Day 1 to 11 post-thawing; 100X magnification.
ioGlutamatergic Neurons TDP‑43 M337V/WT demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following reprogramming
Disease-related TARDBP is expressed in ioGlutamatergic Neurons TDP‑43 M337V/WT following reprogramming
ioGlutamatergic Neurons TDP‑43 M337V/WT are delivered in a cryopreserved format and are programmed to rapidly mature upon revival in the recommended media. The protocol for the generation of these cells is a three-phase process: Induction, which is carried out at bit.bio (Phase 0), Stabilisation for 4 days (Phase 1), and Maintenance (Phase 2) during which the ioGlutamatergic Neurons TDP‑43 M337V/WT mature. Phases 1 and 2 after revival of cells are carried out at the customer site.
ioGlutamatergic Neurons TDP‑43 M337V/WT are compatible with plates ranging from 6 to 384 wells and are available in two vial sizes, tailored to suit your experimental needs with minimal waste.
The recommended seeding density is 30,000 cells/cm2, compared to up to 500,000 cells/cm2 for other available products on the market.
One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plate. One Large vial can plate a minimum of 3.6 x 24-well plate, 5.4 x 96-well plate, or 7.75 x 384-well plates.
Madeleine Garrett | Field Application Specialist | bit.bio
2023
V1
bit.bio
2022
V1
Charles River & bit.bio
2022
Charles River Laboratories & bit.bio
Charles River
Read this blog to find out how experts from across academia and industry are approaching the challenges of reproducibility of in vitro cell models as well as potential solutions.
Further your disease research by pairing our wild type Cells with isogenic disease models.